DMAC — DiaMedica Therapeutics Inc.

Is DMAC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

DiaMedica Therapeutics Inc. (DMAC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $8.38. The rating moved from Strong Oversold to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

DiaMedica Therapeutics Inc. (DMAC) is a small-cap, clinical-stage biopharma with valuation driven largely by upcoming clinical and regulatory milestones and management’s ability to preserve runway. Market context heading into the next session is characterized by consolidation and defensive flows, which mutes aggressive upside from speculative names absent clear positive data. Downside is concentrated in clinical setbacks, cash exhaustion and dilution risk, while upside depends on de‑risking clinical outcomes and successful commercialization or strategic transactions.

Key factors

  • Clinical-stage profile with binary near-term catalysts (data readouts or regulatory interactions) that can materially move valuation
  • Limited public financial disclosure and EDGAR activity available in the provided materials, increasing uncertainty around cash runway and burn
  • Small-cap liquidity and market microstructure: stock likely sensitive to flows, news and biotech sector rotation
  • Broader market tone is measured risk-on with balanced flows, which favors consolidation rather than aggressive moves into early-stage biotechs
  • Defensive flows into large-cap pharma reduce near-term sector tailwinds for smaller specialty biotechs but do not eliminate idiosyncratic upside from positive clinical news

Risks

  • Clinical trial failure or disappointing data that would materially reduce valuation
  • Insufficient cash runway leading to dilution via equity raises or unfavorable financing
  • Regulatory or reimbursement uncertainty that could delay approvals or market access
  • Competitive pressure from larger, better-capitalized pharma companies and adjacent therapeutics
  • Low visibility in social and sell-side coverage, which can amplify volatility and slow price discovery

See today's live rating, score and targets

Members see the live hourly rating for DMAC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.